In vitro effects of melatonin on cell proliferation in a colon adenocarcinoma line

Print
Published on Tuesday, 21 July 2015

Abstract

The effect of melatonin on inhibition of cell growth was studied in CT-26, a murine colon carcinoma-derived cell line.

Cells growing in exponential phase were exposed to low (10(-7)-10(-10) M) and high doses (1, 2 and 3 x 10(-3) M) of melatonin during 24 h.

Synthesis of DNA was measured by 5-bromo-2'-deoxyuridine incorporation. There was no effect at low doses, but a statistically significant correlation was found between the decrease in DNA synthesis and the dose of melatonin used (r = -0.52, P < 0.001).

This implied the following percentages of inhibition: 1 mM, 22%; 2 mM, 25%; 3 mM, 47%.

Potential cell membrane damage by high doses of melatonin was investigated by lactate dehydrogenase measurement and no significant levels were observed. Analysis with a single saturation technique showed no detectable oestradiol receptors in this cell type; therefore, we can assume that the effects occurring with the addition of melatonin were not mediated by modulation of this hormone on oestrogen receptors.

The decreases in cell growth were attributed to a moderate, but significant antiproliferative action of melatonin on this non-hormone-dependent cell line.

 

About this publication.

See also:

- About Melatonin;

- The Di Bella Method (A Fixed Part - Melatonin tablets. From 30-40mg/day up to 200mg/day orally in patients with advanced stage of cancer disease and/or patients without respond to traditional treatments);

- Melatonin with adenosine solubilized in water and stabilized with glycine for oncological treatment - technical preparation, effectivity and clinical findings;

- The Synergism of Somatostatin, Melatonin, Vitamins Prolactin and Estrogen Inhibitors Increased Survival, Objective Response and Performance Status In 297 Cases of Breast Cancer;

- Complete objective response, stable for 5 years, with the Di Bella Method, of multiple-metastatic carcinoma of the breast;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma.